MAIA Biotechnology, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. on April 2, 2024, covering events occurring on April 1, 2024. The company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "MAIA".
Key Financial Metrics
The filing does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on executive compensation adjustments.
Material Changes
Effective April 1, 2024, the company amended the employment agreement for Jeffrey Himmelreich. The material changes include:
- Base Salary: Increased to $250,000.
- Target Annual Bonus: Increased to 25% of the Base Salary.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, risks, contingencies, or unusual items. The document is limited to the disclosure of the executive compensation adjustment under Item 5.02.
Key Facts for Investor Verification
- Verify the effective date of the compensation increase for Jeffrey Himmelreich (April 1, 2024).
- Confirm the new base salary amount ($250,000) and bonus structure (25% of base).
- Note that this filing does not contain updated financial performance data or liquidity status.